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1. Introduction 
Until recently, alcohol abuse and dependence, as described by the Diagnostic and 
Statistical Manual of Mental Disorders (DSM IV; (American Psychiatric Association, 2000)), 
were the most studied problematic outcomes for the clinical consequences of alcohol 
consumption. As diagnostic measures, alcohol abuse or dependence were restricted to classifying 
individuals as “affected” or “unaffected” with little sensitivity for underlying profiles of 
endorsement of the 11 symptoms (7 for dependence and 4 for abuse) that were being used to 
describe alcohol-related behavior. Hence, especially when used as research outcomes, there was 
significant concern about DSM-IV diagnoses of abuse or dependence to (1) reflect individual 
differences with respect to the underlying constructs believed to be represented by the 11 
symptoms that research showed is indicative of a single continuum (Hasin and Beseler, 2009, 
NRC, 2011), and (2) reflect differences in severity across all of the addiction domains (i.e., (a) a 
compulsion to seek and/or take alcohol, (b) loss of control over alcohol consumption, and (c) 
emergence of a negative emotional state) captured by the symptoms. Not surprising, recent 
studies and recommendations which arose out of the Substance Related Disorders Working 
Group of the DSM-5 taskforce suggested that diagnosis of an alcohol use disorder (AUD) be 
based on 11 symptoms derived from the integration of the DSM-IV dependence symptoms with 
three of the DSM-IV abuse criteria (i.e., less ‘recurrent legal problems’) and an alcohol craving 
criterion. Notably, a continuum should be used to describe AUDs (i.e., unaffected = endorsing 0-
1 out of 11 symptoms; mild = endorsing 2-3 out of 11 symptoms; moderate = endorsing 4-5 
symptoms out of 11 symptoms, and severe = endorsing 6 or more out of 11 symptoms). 
As part of the debate on the utility and suitability of the dichotomous measure of alcohol 
dependence (AD), as opposed to a continuous measure of alcohol problem severity in genetic 
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research, we recently examined the assumption of genetic homogeneity across all DSM-IV 
dependence symptoms using genomewide SNP data (Palmer et al., 2015b). Validation of the 
assumption across the seven symptoms affirmed the utility of a factor score across the indices as 
much of the observed genetic variance was shared across the comorbid items, suggesting 
common genetic factors underlie the addiction state (Koob et al., 2014), which is reflected in 
behavioral symptoms included in DSM-5 AUD (American Psychiatric Association, 2013). The 
results also indicated that effects observed upon a latent continuum of AD risk (as indicated by 
DSM-IV dependence symptoms) may not be truly reflective of the entire liability continuum, as 
there also exists symptom-specific genetic variance that may be imparted by the study of 
multiple factors (as previously suggested using a multivariate twin study approach (Kendler et 
al., 2012)). This latter point was recently reflected in a report by Hart and colleagues which 
showed variation in the association between common genetic variants within the alcohol 
dehydrogenase gene (ADH1B) and each of the diagnostic symptoms of AD (Hart et al., 2016). In 
perspective, Hart and colleagues were able to determine that previously observed AD 
genomewide association study (GWAS) associations (Gelernter et al., 2014), for example, in 
their subjects of African ancestry (i.e., rs2066702 with AD), were primarily driven by signals 
specific to phenotypic variation in the symptoms ‘Tolerance’ and ‘Much time spent 
using/recovering from the effects of alcohol’. This observation is important as phenotype-
genotypic associations from GWAS are used to inform gene function studies in tissue/cell 
culture and/or model organisms.  
Altogether, our previous study of DSM-IV symptoms and these recent molecular studies 
of DSM-IV and DSM-5 AUD underscore the need to characterize the multivariate genetic 
architecture of DSM-5 AUD symptoms. The present paper uses subjects of European ancestry 
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from the Study of Addiction: Genetics and Environment Consortium to characterize the genetic 
architecture of the 11 DSM-5 AUD symptoms. It builds upon our previous report by comparing 
several models that test the assumption of genetic homogeneity across AUD symptoms. The 
goals of this study were to: 
1. Examine the genomewide additive genetic contribution to DSM-5 AUD symptoms 
(i.e., former DSM-IV abuse and dependence symptoms along with alcohol craving), 
and 
2. Determine the most parsimonious model of the additive genetic covariance across 
DSM-5 AUD symptoms. 
 
2. Materials and Methods 
2.1 Sample 
Data were drawn from the Study of Addiction: Genetics and Environment (SAGE) 
(Bierut et al., 2010). Analyses focused on 2596 unrelated individuals (44% male; mean 
age=38.58 years [standard deviation (SD)=9.80]) of European ancestry, which was confirmed 
using principal component analysis. All subjects were no more related than second 
cousins(Palmer et al., 2015a). Additional details on SAGE are available at 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000092.v1.p1. 
 
2.2 Phenotype 
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The dependent variables of interest for the current study were DSM-5 AUD symptoms 
(coded as present or absent) that were approximated from the Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA) (Bucholz et al., 1994, Hesselbrock et al., 1999). Specifically, 
DSM-IV alcohol abuse and dependence symptoms were extracted from the SSAGA interview 
and combined with a separate measure of alcohol craving that was also included in the 
assessment. Craving was defined in the SSAGA as endorsement of the item ‘In situations where 
you couldn’t drink, did you ever have such a strong desire for it that you couldn’t think of 
anything else’; respondents who answered yes received a score of 1; ‘No’ was coded as 0; non-
users received a missing value (Agrawal et al., 2013). All responses were limited to individuals 
with a history of exposure to alcohol (and possibly other substances). 
 
2.3 Genotyping and Quality Control 
Subjects within SAGE were genotyped using the ILLUMINA Human 1M platform. 
Quality control of the sample included: (1) removal of non-autosomal SNPs, (2) removal of 
markers with an allele frequency <1%, (3) exclusion of markers with a call rate less than 98%, 
and (4) removal of SNPs that show evidence of deviation from Hardy–Weinberg Equilibrium 
(HWE; p-value < 0.0001) to minimize any possible bias due to assortative mating (Agrawal et 
al., 2006, Grant et al., 2007). A total of 796,125 autosomal SNPs were carried forward in the 
analyses. These same SNPs were also used to conduct the aforementioned selection of distantly 
related EA individuals from the entire set of SAGE participants (N=4121) (i.e., using the 
software package: Genomewide Complex Trait Analysis [GCTA])(Yang et al., 2010, Lee et al., 
2011, Yang et al., 2011).  
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2.4 Statistical Analysis 
The EA sample (N=2596) was used in all parts of the analytical framework, which 
included (1) development of a phenotypic factor comprised of shared variance among DSM-5 
items using randomly selected individuals to create two halves of the sample for exploratory and 
confirmatory models (conducted in Mplus version 7) (Muthén and Muthén, (1998-2012)), (2) 
Genomic-relatedness-matrix restricted maximum likelihood (GREML; implemented in GCTA) 
analysis of the individual symptoms, AUD factor score (standardized [mean=0, standard 
deviation=1]), AUD diagnosis (i.e., 0=0-1 symptoms, 1=2-11 symptoms),  and log-transformed 
DSM-5 AUD diagnosis severity (i.e., Ln(1+DSM-5 AUD diagnosis [0=0-1 symptoms, 1=mild 
[2-3 symptoms], 2=moderate[4-5 symptoms], 3=severe [7+ symptoms]]). 
 
2.4.1 Estimation of Additive Genetic Effects 
GREML was used to determine the SNP-heritability (h
2
SNP) of DSM-5 AUD factor score, 
severity (i.e., mild, moderate, severe), diagnosis (i.e., control vs. case [i.e., 2+ symptoms]), and 
individual symptoms. This approach was implemented using GCTA. GREML utilizes a genetic 
relationship matrix to decompose phenotypic variance into genetic effects captured by the 
common SNPs and error variance. The SNP-heritability estimates were transformed on the 
liability scale to account for distributional differences in prevalence of AUD and endorsement of 
AUD symptoms observed in this case/control study versus the general population (i.e. the 
proportion of cases in this study is higher than what is seen in the population). Lifetime 
population prevalence estimates that were used to transform the SNP-heritability and co-
heritability estimates were calculated for DSM-5 AUD diagnosis and individual symptoms from 
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the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, wave 1; 
N=43,093) (Hasin and Grant, 2015) and, for craving from the National Longitudinal Alcohol 
Epidemiologic Survey  (NLAES)(Grant et al., 2003). Craving in NLAES was defined by 
endorsement of at least one of two possible items: ‘Want to drink so badly that you couldn’t 
think of anything else’ and ‘Feel a very strong desire or urge to drink’. Prevalence was calculated 
for individuals in NESARC and NLAES who (1) self-reported non-Hispanic White ethnicity, (2) 
were aged 18-79 years, and (3) reported lifetime exposure to alcohol (see Table 2). All analyses 
controlled for gender, age, and the first five ancestral principal components. 
2.4.2 Estimation of the Covariance Explained by SNPs 
Two multivariate approaches were used to determine whether the same genetic factors 
contribute to the phenotypic correlation between AUD symptoms: (1) The Common Pathway 
Model (CPM) and (2) Exploratory Genetic Factor Analysis (EGFA). In addition, the EGFA was 
followed up with three confirmatory factor analyses to determine the most parsimonious genetic 
architecture across the criteria. Three multivariate models were tested: (a) a common genetic 
factor model, (b) a 2- factor model where factor-1 was indicated by the three former DSM-IV 
abuse symptoms and craving and factor-2 was indicated by the seven former DSM-IV 
dependence items), and (c) a 2-genetic factor model in which craving was allowed to cross-load 
across the factors). The CFA models were compared using the Akaike Information Criteria 
(AIC) (Akaike, 1973).  
In the CPM approach, a latent variable representing the shared variance across all 
symptoms was decomposed into genetic and error variance in two steps. First, an exploratory 
factor model (EFA) was fitted to a random selected half of the sample to determine the 
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phenotypic factor structure of AUD; this model was then confirmed using confirmatory factor 
analysis (CFA) of the remaining half of the sample. AUD factor scores were extracted from the 
full sample and used in the analyses described above. In the EGFA approach, which represents a 
multivariate extension of GREML, a factor analysis was conducted on the 11x11 
variance/covariance matrix of inter-criterion bivariate SNP heritabilities through a series of steps. 
First, GREML was used to estimate bivariate SNP genetic covariance estimates across each pair 
of criteria. Next, these estimates were used to construct an 11x11 genetic variance/covariance 
matrix. Because covariance matrices constructed from bivariate estimates may not be positive 
definite, we determined the nearest positive definite variance/covariance matrix using the 
Higham algorithm (Higham, 2002) within the nearPD package in R, version 3.4.0 (Team, 2017). 
Finally, we conducted factor analysis of the variance/covariance matrix to determine the factor 
structure of the multivariate genetic relationship between AUD symptoms. To determine the 
number of genetic factors, we employed Parallel Analysis implemented in R with the nFactors 
package. This approach has been shown to outperform other methods under a variety of 
conditions (Ledesma and Valero-Mora, 2007). A factor was retained if the eigenvalue of the 
genetic variance/covariance matrix was greater than the 95
th
 percentile of the distribution of 
eigenvalues derived from random data (generated with 1000 iterations). All analyses for the 
CPM approach were conducted in Mplus and all analyses for the EGFA approach were 
conducted in R using the OpenMx and Psych packages; bootstrapped confidence intervals for the 
EGFA path loadings were obtained using 1000 replicates. 
 
3. Results 
3.1 Symptom levels and phenotypic covariance in SAGE 
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The prevalence of endorsement for each AUD symptom and the tetrachoric correlations 
among all items are presented in Table 1. Approximately 66.49% (n = 1716) of participants met 
the diagnostic symptoms for DSM-5 AUD. Phenotypic tetrachoric correlations were high, 
indicating that symptoms frequently co-occur, and ranged from 0.73 - 0.91 (with the lowest 
correlations being 0.73 between craving and two criteria: tolerance and ‘Taking alcohol in larger 
amounts or over a longer period than was intended’). 
 
3.2 Univariate additive genetic effects on DSM-5 AUD diagnosis and symptoms 
Common SNPs explained 14% (standard error [SE] = 0.21, p = 0.24 of the variation in 
DSM-5 AUD diagnosis and 22% (SE = 0.13, p = 0.04) of the variation in AUD severity (i.e., ln-
transformed DSM-5 AUD categories). Across the 11 AUD symptoms, SNP-heritability estimates 
varied from 13% (Great time spent using/recovering) to 39% (Using longer than intended), with 
five of the 11 items reaching significance (p < 0.05) and four items reaching nominal 
significance (p < 0.10) (see Table 2).   
 
3.3 Analysis of the genetic covariance across DSM-5 AUD symptoms 
CPM approach. Exploratory and confirmatory analyses of phenotypic data revealed a 
single latent variable (AUD factor; see Table 3). All items loaded on the single latent factor 
>0.84. Excellent model fit (RMSEA < 0.05, CFI/TLI > 0.95) supports the CPM that describes 
the phenotypic relationships between symptoms as arising from an unobserved latent trait. 
Common SNPs explained 36% (standard error [SE] = 0.13, p = 0.002) of the variation in the 
AUD factor score.    
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EGFA Approach. Across AUD symptoms, the pattern of inter-symptom SNP 
correlations was generally high (strong rG-SNP > 0.60), suggesting shared genetic variance across 
symptoms (see right side of Table 2). However it is important to recognize that several of these 
estimates were inflated in instances where the h
2
SNP of at least one of the symptoms was non-
significant (i.e., only a small proportion of the phenotypic variance in the DSM-5 criterion is 
explained by genetic variation). Analysis of the 11x11 genetic variance/covariance matrix 
suggested a single genetic factor parsimoniously describes much of the shared genetic variance 
across the 11 criteria (see Supplementary Table S1 for the genetic variance/covariance matrix). 
Parallel analysis indicated that the first eigenvalue derived from this matrix exceeded the 95
th
 
percentile of the distribution of eigenvalues derived from random data (see Figure 1). Genetic 
factor loadings for AUD symptoms were high (>0.60) and the total genetic variance of each 
criteria attributable to the factor ranged from 38% for ‘craving’ to 89% for ‘failure to fulfill 
major roles’ (see Table 4 for a summary of factor loadings and percent variance explained in the 
EGFA). Our analysis of competing models of additive genetic effects on AUD indicated that the 
model containing a single genetic factor provided the best fit to the data (χ2=49905.53, degrees 
of freedom (df)=44, AIC=49817.53). On the contrary, the two-factor genetic model that allowed 
for a correlation between the genetic factors was less parsimonious (compared to the one-factor 
model: ΔAIC=4046.55), but estimated the correlation between the abuse and dependence factors 
at 1.00 [95% confidence interval=0.99, 1.00]. We also examined a bi-genetic factor model that 
allowed craving to cross-load across the factors; results were similar and this adjusted model fit 
the data slightly worse (compared to the one-factor model: ΔAIC=4048.55). Overall, both the 
EGFA and CFA suggest shared additive genetic effects across symptoms of DSM-5 AUD. 
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4. Discussion 
This study examined the expanded definition of diagnostic criteria contributing to AUD 
as defined by the American Psychiatric Association’s DSM-5. Additive genetic effects are 
partially shared across DSM-5 symptoms of AUD, with genetic correlations > 0.80 for several 
criteria. However, correlations across some criteria were as low as 0.21 (e.g., craving and time 
spent), suggesting the possibility of a violation of the assumption of genetic homogeneity 
underlying the AUD phenotype, but this was not a common occurrence (i.e. percentage of 
correlations >0.3=98%, >0.6=78%, and >0.8=42%). Notably, while the standard errors for some 
of these correlation estimates was fairly large (e.g., rG=0.21 (SE=0.73) for the association 
between craving and ‘A great deal of time spent to obtain/use/recover from alcohol’), other 
correlations were more precise (e.g., rG=1.00 (SE=0.20) for ‘Recurrent use resulting in failure to 
fulfill major roles’ associated with ‘Given up or cut back on important activities in order to drink’), and 
thus, the hypothesis of underlying genetic homogeneity cannot be fully rejected. However, it is 
possible that the ability to localize genetic loci for AUDs is likely to be reduced when using 
scoring methods that ignore the fact that symptoms are influenced by shared and non-shared 
genetic factors (i.e., just as there are a multitude of symptom profiles that lead to an AUD 
diagnosis, the respective genetic risk profiles for these various symptom profiles may vary 
accordingly). 
The incorporation of previous DSM-IV abuse symptoms and craving for alcohol 
enhanced the definition of problematic alcohol use. Estimated effects of genetic variation on the 
newly added alcohol symptoms ranged from 0.10-0.37. Notably, the SNP-heritability of DSM-5 
AUD factor was similar to what was previously reported for DSM-IV alcohol dependence as a 
factor score (Palmer et al., 2015b, Brick et al., 2017). Moreover, our examinations of the genetic 
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influences on the 11 symptoms supports the underlying assumptions of (1) a single underlying 
dimension of risk that is captured by the symptoms, and (2) common genetic pathways that 
contribute to ‘craving’, ‘using longer than intended’, ‘withdrawal’, and the other symptoms. 
These findings align with previous examinations of alcohol symptoms in genetically informed 
samples, which suggested a single underlying latent trait that is polygenic in nature. It was for 
this reason that we opted to use Genomic Restricted maximum likelihood (GREML) to 
understand the relationship among the 11 AUD symptoms because our sample sizes precluded 
the use of genomewide association analysis which would have resulted in biased SNP-estimates 
that reflect only a small portion of the phenotypic heritability (i.e., missing heritability; (Manolio 
et al., 2009)). In the current analysis, we were interested in quantifying the heritability and co-
heritability due to common variation. In GREML, there is less emphasis on detecting the small 
effects of the common variants, but instead more emphasis on aggregated effects. Our 
examination of alternative factorial configurations of the criteria (i.e., correlated abuse and 
dependence genetic factors) provides novel evidence supporting the assumption that the genetic 
architecture across AUD symptoms is largely shared. Indeed, as the data suggest, GWAS aimed 
at the factors of tolerance, loss of control and withdrawal (Kendler et al., 2011) may yield loci 
distinct from those identified using a unidimensional factor score or diagnosis, because of limited 
power to detect such specificity and also because of AUD-symptom-specific genetic variance. 
As such, future works should consider analyzing AUD measures in their various forms. 
Using these approaches, for the first time we report on the genomewide SNP-heritability 
of alcohol craving. Similar to our earlier report using a larger, but ancestrally mixed SAGE 
sample (Agrawal et al., 2013), 21% percent of the total sample endorsed alcohol craving. The 
univariate SNP-heritability of 0.24 (SE=0.21; post-hoc power=0.57) for craving did not meet our 
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criteria for statistical significance, however, the high loading (>0.85) of the craving item on the 
latent AUD factor, which had a SNP-heritability of 0.36 (standard error [SE] = 0.13), suggests 
genetic effects on craving. Notably, our analysis of the genetic effects across symptoms 
suggested some differential effects of genomewide SNPs across AUD symptoms, but craving 
was least explained by the common genetic factors. A review of the alcohol literature identified 
two studies supporting the role of variation across the alpha-synuclein gene (SNCA) and alcohol 
craving. α-synuclein has been shown to play a role in dopamine functioning across several 
regions of the brain (e.g., inhibiting dopamine synthesis; (Perez et al., 2002)) – making it a 
candidate for addiction research. In regards to alcohol, Foroud et al. (Foroud et al., 2007), 
identified haplotypes of SNPs in SNCA that were associated with alcohol craving, but not DSM-
IV alcohol dependence diagnosis, supporting our argument here that the study of individual 
symptoms for AUD may at times point to sources of liability that may be overlooked when 
studying only the shared variance across AUD symptoms. More recently, our analysis of genes 
in the dopamine pathway (i.e., DRD1, DRD2, DRD3, DRD4, SLC6A3, as well as SNCA) also 
suggested common and specific effects from variants in these genes across craving and alcohol 
dependence (i.e., without craving) (Agrawal et al., 2013). It is important to note that for the 
current analyses, craving was assessed using a single item (strong desire to use so couldn’t think 
of anything else). Prior work has contrasted the contributions of varying definitions of craving on 
AUD diagnosis (Keyes et al., 2011); the NESARC includes two items that effectively separate 
“strong desire or urge” from “couldn’t think about anything else” with the former being more 
commonly reported in population samples than the latter. However, “strong desire” is 
incorporated into the International Classification of Disease (ICD-10) diagnosis of AUD 
(Yoshimura et al., 2016) and is part of the phrasing of the corresponding DSM-5 item. Therefore, 
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our single item adequately captures the phenomenon of craving, although future studies might 
wish to explore alternative conceptualizations of the construct.  
The SNP-heritability of DSM-5 AUD diagnosis (h
2
SNP=0.14) was not significant but 
approximates the estimate of 0.09 from a recent GWAS meta-analysis of DSM-IV alcohol 
dependence (Sanchez-Roige et al., 2018).  In contrast, SNP-heritability for the AUD factor score 
(0.36) and for the AUD severity score (0.22) were significant and higher. The use of a 
quantitative index of liability likely increased sensitivity to capture genetic effects and supports 
the transition from a binary (DSM-IV) to categorical (DSM-5) definition of AUD. However, the 
modest reduction in heritability when using the AUD severity score, which represents DSM-5 
categories implies some compression of meaningful variability that the full spectrum of scores 
affords. Indeed, a symptom count was used amongst the few successful GWAS of alcohol 
dependence (Gelernter et al., 2014). As a symptom count is similar to a unidimensional factor 
score, our analyses support the use of such symptom counts, potentially augmented to even 
include indices of alcohol consumption (Saha et al., 2007), as well as other comorbid 
internalizing and externalizing type disorders that have evidenced genetic overlap (Cerda et al., 
2010).  
Important considerations for the current study were our inability to model dominance and 
epistatic effects from genomewide loci, which is a growing area of interest in the field of 
psychiatric genetics, but is an approach that was not feasible with our current sample size. As 
such, readers should interpret these effects as the cumulative/additive effect of genomewide 
SNPs, which is akin to the additive genetic variance component (A) typically examined in the 
twin literature and that largely contributes to the correlation among relatives. Likewise, an 
examination of gender was prohibited due to sample size, but twin studies that have explored 
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gender differences (i.e., qualitative and quantitative) have been mixed (Verhulst et al., 2015). 
Another important consideration to arise from this study is, the varied h
2
SNP effect sizes across 
symptoms suggest that larger samples are needed to study individual symptoms with limited 
(<0.30) genetic effects, particularly if the variance across the set of SNPs influencing each 
symptom is not constant. We have cautiously interpreted our study findings because of the 
limited power to detect modest SNP-heritability estimates and genetic correlations, especially in 
instances where the SNP-heritability of a pair of items was low and non-significant. As is the 
case with twin and family studies (Verhulst, 2017), cautious interpretation is warranted when 
estimating and interpreting genetic correlations between phenotypes when the magnitude of the 
genetic effect is limited. To aid in our interpretation of these data we modeled the raw genetic 
variance/covariance matrix to minimize bias. Similarly, we compared several multivariate factor 
models of the genetic covariance matrix and report bootstrapped confidence intervals of the 
loadings from the most parsimonious model. Altogether, when considering these factor, the 
pattern of results provide preliminary evidence to suggest that studying the shared liability across 
all of the DSM symptoms is a more genetically sensitive (i.e., evidencing a moderate heritability 
[0.30-0.60]) and parsimonious phenotype, since the loci likely reflects the lowest common 
denominator/factors for AUD.  
In conclusion, we discovered that the APA’s DSM-5 definition of alcohol-related 
problems is a heritable phenotype with varying genetic effects across the individual symptoms 
with both shared and non-shared genetic variance between them. Though tentative and in need of 
replication in larger samples, these findings lend support to the use of composite scores, such as 
factor scores or symptom count as phenotype, as well as the application of genomic structural 
equation model methods in future studies.  
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Figure Citation 
 
Figure 1. Parallel analysis of 11x11 genetic covariance matrix for DSM-5 AUD symptoms 
Observed eigenvalues (solid line) are compared to 95 percentile of the eigenvalue distribution 
(dashed line [with standard error]) derived from 1000 randomly generated datasets. All factors 
left of where the solid lines first intersects with the dashed line are retained and their effects 
described in Table 4. 
Table 1. Sample prevalence and associations among DSM-5 alcohol dependence symptoms. 
  
Sample 
Prevalence   Tetrachoric Correlation 
Symptom N %   Sx1 Sx2 Sx3 Sx4 Sx5 Sx6 Sx7 Sx8 Sx9 Sx10 Sx11 
Sx1 904 34.8   1.00                     
Sx2 1677 64.6   0.81 1.00                   
Sx3 1188 45.8   0.83 0.84 1.00                 
Sx4 1263 48.7   0.75 0.74 0.76 1.00               
Sx5 616 23.7   0.83 0.81 0.83 0.76 1.00             
Sx6 1597 61.5   0.77 0.79 0.80 0.75 0.74 1.00           
Sx7 1110 42.8   0.81 0.75 0.82 0.76 0.83 0.81 1.00         
Sx8 704 27.1   0.86 0.80 0.83 0.76 0.84 0.77 0.79 1.00       
Sx9 692 26.7   0.91 0.84 0.87 0.78 0.85 0.76 0.84 0.89 1.00     
Sx10 1249 48.1   0.84 0.86 0.83 0.77 0.85 0.81 0.80 0.81 0.85 1.00   
Sx11 545 21.0   0.82 0.77 0.81 0.73 0.87 0.73 0.81 0.83 0.86 0.82 1.00 
Sx1: Recurrent use resulting in failure to fulfill major role obligations at work, school, or home 
Sx2: Recurrent use in situations in which it is physically hazardous 
Sx3: Continued use despite persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the alcohol 
Sx4: Tolerance 
Sx5: Withdrawal 
Sx6: Taken in larger amounts or over a longer period than was intended 
Sx7: Persistent desire or there are unsuccessful efforts to cut down or control alcohol use 
Sx8: A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects 
Sx9: Given up or cut back on important activities in order to drink  
Sx10: Continued to use alcohol despite knowledge of having persistent or recurrent physical or psychological problem that is likely to have 
been caused by the alcohol 
Sx11: Craving 
 
Table 1
Table 2. Univariate SNP heritability (h2SNP), bivariate correlations, and standard errors (SE) 
Symptom 
Population 
Prevalence a h2SNP 
  Inter-symptom genetic correlations 
  Sx1 Sx2 Sx3 Sx4 Sx5 Sx6 Sx7 Sx8 Sx9 Sx10 Sx11 
Sx1 4.8 0.18 (0.12)b   1.00                     
Sx2 31.6 0.33 (0.20)*   1.00 (0.88) 1.00                   
Sx3 11.8 0.37 (0.14)**   1.00 (0.25)* 0.57 (0.24)b 1.00                 
Sx4 25.5 0.34 (0.18)*   0.87 (0.29)* 0.81 (0.28)* 0.53 (0.24)b 1.00               
Sx5 18.3 0.36 (0.23)b   1.00 (0.44) 0.71 (0.33)b 0.98 (0.26)** 0.46 (0.33) 1.00             
Sx6 23.9 0.39 (0.20)*   1.00 (0.38) 0.64 (0.27)b 0.88 (0.21)** 0.58 (0.27)b 0.64 (0.32)b 1.00           
Sx7 30.8 0.24 (0.18)b   1.00 (0.47) 1.00 (0.48) 0.70 (0.25)b 1.00 (0.31)* 0.94 (0.33)* 1.00 (0.36) 1.00         
Sx8 13.6 0.13 (0.18)   1.00 (0.51) 0.85 (0.56) 0.75 (0.44)b 0.49 (0.49)b 0.65 (0.44) 0.89 (0.59)b 0.87 (0.53) 1.00       
Sx9 3.7 0.28 (0.13)*   1.00 (0.20)* 1.00 (0.43) 0.74 (0.20)* 0.53 (0.27)b 0.87 (0.22)* 0.64 (0.27)* 0.96 (0.29)* 0.47 (0.40) 1.00     
Sx10 11.7 0.31 (0.14)*   1.00 (0.24)* 0.81 (0.21)* 0.79 (0.17)** 0.72 (0.23)* 0.61 (0.27)b 0.75 (0.22)* 0.86 (0.26)* 0.95 (0.50)* 0.82 (0.20)* 1.00   
Sx11 9.9 0.24 (0.21)   0.73 (0.37) 0.66 (0.42) 0.54 (0.32) 0.68 (0.36)b 1.00 (0.59) 0.34 (0.42) 0.38 (0.47) 0.21 (0.73) 0.73 (0.28)b 0.61 (0.34) 1.00 
                              
Composite phenotypes                           
DSM-5 AUD diagnosis 0.14 (0.21)                         
DSM-5 AUD severity 0.22 (0.13)*                         
DSM-5 AUD factor 0.36 (0.13)**                         
Table 2
Notation: a Lifetime population prevalence of symptoms 1 thru 10 were derived from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, wave 1; N=43,093); the prevalence for symptom 11 
(craving) was derived from National Longitudinal Alcohol Epidemiologic Survey  (NLAES). Population prevalence rates were used to transform the SNP-heritability and co-heritability estimates. b - p< 0.10, * - p < 0.05, ** - 
p< 0.01. Abbreviations:                                                                                                                                                                                                                                                                                                                         Sx1: 
Recurrent use resulting in failure to fulfill major role obligations at work, school, or home 
Sx2: Recurrent use in situations in which it is physically hazardous 
Sx3: Continued use despite persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the alcohol 
Sx4: Tolerance 
Sx5: Withdrawal 
Sx6: Taken in larger amounts or over a longer period than was intended 
Sx7: Persistent desire or ther are unsuccessful efforts to cut down or control alcohol use 
Sx8: A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects 
Sx9: Given up or cut back on important activities in order to drink  
Sx10: Continued to use alcohl despite knowledge of having persistent or recurrent physical or psychological problem that is likely to have been caused by the alcohol 
Sx11: Craving 
 
Table 3. CPM Approach: Exploratory and confirmatory factor models of alcohol dependence symptoms 
 
Exploratory 
 
Confirmatory 
Parameters 
Sample-1 
EFA 
(n=1298) 
Sample-2 
CFA 
(n=1298)   
Full Sample CFA 
(N=2596) 
Fit statistics 
    χ2 109.596 100.862 
 
179.382 
df 44 44 
 
44 
RMSEA 0.034 0.032 
 
0.034 
CFI -- 0.999 
 
0.998 
TLI -- 0.998 
 
0.998 
RMSR  0.026 -- 
 
-- 
Factor loadings 
    Sx1: Recurrent use resulting in failure to fulfill major roles 0.927 0.921 
 
0.924 
Sx2: Recurrent use in situations in which it is physically hazardous 0.897 0.898 
 
0.897 
Sx3: Continued use despite persistent or recurrent social problems 0.916 0.909 
 
0.912 
Sx4: Tolerance 0.844 0.823 
 
0.833 
Sx5: Withdrawal 0.907 0.927 
 
0.917 
Sx6: Taken in larger amounts or over a longer period than was intended 0.867 0.859 
 
0.863 
Sx7: Persistent desire to cut down or control alcohol use 0.873 0.899 
 
0.885 
Sx8: A great deal of time spent to obtain/use/recover from alcohol 0.935 0.891 
 
0.913 
Sx9: Given up or cut back on important activities in order to drink  0.952 0.956 
 
0.954 
Sx10: Continued to use alcohol despite knowledge physical or psychological problems 0.926 0.909 
 
0.917 
Sx11: Craving 0.894 0.910   0.900 
Note: EFA = Exploratory factor analysis; CFA = Confirmatory factor analysis; df = degrees of freedom; RMSEA = Root Mean Square Error Of 
Approximation; CFI = Comparative Fit Index; TLI = Tucker Lewis Index; RMSR = Root Mean Square Residual 
 
Table 3
Table 4. EGFA Approach: Genetic variance in each DSM-5 symptom explained by common genetic factor. 
Symptom 
Factor Loading 
[95% CI] 
% Total Genetic 
Variance Explained 
Sx1: Recurrent use resulting in failure to fulfill major roles 0.93 [0.92,0.94]  87% 
Sx2: Recurrent use in situations in which it is physically hazardous 0.81 [0.80,0.83] 66% 
Sx3: Continued use despite persistent or recurrent social problems 0.86 [0.85,0.87] 74% 
Sx4: Tolerance 0.74 [0.73,0.76] 55% 
Sx5: Withdrawal 0.80 [0.79,0.82] 64% 
Sx6: Taken in larger amounts or over a longer period than was intended 0.83 [0.82,0.84] 69% 
Sx7: Persistent desire to cut down or control alcohol use 0.90 [0.89,0.91] 81% 
Sx8: A great deal of time spent to obtain/use/recover from alcohol 0.76 [0.75,0.78] 58% 
Sx9: Given up or cut back on important activities in order to drink  0.85 [0.84,0.86] 72% 
Sx10: Continued to use alcohol despite knowledge physical or psychological problems 0.91 [0.90, 0.92] 83% 
Sx11: Craving 0.61 [0.59, 0.64] 37% 
Table showing standardized factor loadings of the exploratory genetic factor analysis along with 95% confidence intervals and squared standardized 
factor loading (i.e., percent of genetic variance explained). 
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HIGHLIGHTS 
 The SNP-heritability of DSM-5 AUD varies across the 11 criteria. 
 Genetic effects on most DSM-5 symptoms (except craving) largely overlap. 
 The AUD factor is more heritable (36%) than symptom count (22%) and diagnosis (14%). 
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